Pseudolymphomas of the skin (overview)L98.8

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 03.12.2022

Dieser Artikel auf Deutsch

Synonym(s)

Cutaneous pseudolymphoma; Pseudolymphoma; Reticulocytosis

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

HistoryThis section has been translated automatically.

Stag and Luke 1965

DefinitionThis section has been translated automatically.

Benign, histologically and clinically not always clearly distinguishable from malignant lymphomas of the skin, reactive, polyclonal, self-limited, lymphoreticular proliferations of the skin of different etiology and different clinical morphology.

ClassificationThis section has been translated automatically.

According to etiology and clinical presentation, one divides:

According to immunophenotype, pseudolymphomas can be divided as follows:

EtiopathogenesisThis section has been translated automatically.

Various causes possible, see Table 1.

HistologyThis section has been translated automatically.

Dense, striated, lymphohistiocytic infiltrate, cell polymorphism, epidermal and vascular involvement Pleomorphies, hyperchromasia or mitoses may be signs of malignancy, but are rare.

Direct ImmunofluorescenceThis section has been translated automatically.

Mature B and T cells.

DiagnosisThis section has been translated automatically.

Clinic, histology, PCR, Southern blot, immunohistochemistry.

The expression of monoclonal kappa- or lambda- light chains is in contrast to the polyclonal expression in reactive hyperplasia (pseudolymphoma) generally considered as malignant event. However, B- and T-cell pseudoclones are found in up to 20% of cases of pseudolymphomas.

In cutaneous B-cell lymphomas and cutaneous T-cell lymphomas the clonal rearrangement of the Ig chains can be detected either by immunohistochemical analysis with monoclonal antibodies or by immunogenotyping using Southern blot or PCR. The immunohistochemical technique has the advantage of the exact allocation of the antigen in the tissue, but is less sensitive (background staining). Southern blotting can make clonal cells visible in more than 5% of the cells of the lesion; the PCR technique is more sensitive with detection of < 0.1% of clonal cells.

TherapyThis section has been translated automatically.

Treatment of the underlying disease if known, see there.

Progression/forecastThis section has been translated automatically.

Favourable (monitoring of the clinical course and ensuring lack of system participation).

Note(s)This section has been translated automatically.

The term "pseudolymphoma" covers a group of different clinical and histological entities that differ in their clinical and histological appearance and immunophenotype. It is desirable to name the known and historically founded terms in this way. In a larger French survey series among dermatologists and pathologists (122 dermatologists, 64 pathologists) it became obvious that the term "pseudolyphoma" has neither from clinical morphological view nor from histopathological view a uniform identification (Levy E et al. 2013).

LiteratureThis section has been translated automatically.

  1. Braun RP et al (2000) Cutaneous pseudolymphoma, lymphomatoid contact dermatitis type, as an unusual cause of symmetrical upper eyelid nodules. Br J Dermatol 143: 411-414
  2. Böer A et al (2008) Pseudoclonality in cutaneous pseudolymphomas: a pitfall in interpretation of rearragnement studies. Br J Dermatol 159: 394-402
  3. Cogrel O et al (2001) Sodium valproate-induced cutaneous pseudolymphoma followed by recurrence with carbamazepine. Br J Dermatol 144: 1235-1238
  4. Gerlini G et al (2003) Specific immune therapy-related cutaneous B-cell pseudolymphoma with following dissemination. J Eur Acad Dermatol Venereol 17: 208-212
  5. Stag P, Luke R (1965) Reactive pseudolymphoma, nodular type. Arch Derm 19: 408-409
  6. Hussein MR (2013) Cutaneous pseudolymphomas: inflammatory reactive proliferations. Expert Rev Hematol 6:713-733.

  7. Kulow BF et al (2002) Progression of cutaneous B-cell pseudolymphoma to cutaneous B-cell lymphoma. J Cutan Med Surg 6: 519-528

  8. Leinweber B et al (2006) Histopathologic features of cutaneous herpes virus infections (herpes simplex
    ,herpes varicella/zoster): a broad spectrum of presentations with commonpseudolymphomatous
    aspects. On J Surg Pathol 30:50-58.

  9. Levy E et al (2013) Pseudolymphoma of the skin: ambiguous terminology: a survey among dermatologists and pathologists. Ann Dermatol Venereol 140:105-111.

  10. Marchesi A et al (2014) Tattoo ink-related cutaneous pseudolymphoma: a rare but significant complication. Case report and review of the literature. Aesthetic Plast Surgery 38:471-478
  11. Moreno-Ramirez D et al (2003) Cutaneous pseudolymphoma in association with molluscum contagiosum in an elderly patient. J Cutan pathogen 30: 473-475
  12. Pulitzer MP et al (2013)CD30+ lymphomatoid drug reactions. At J Dermatopathol 35:343-350
  13. Ter-Nedden L (2018) test your expertise. Pseudolymphoma in herpes simplex infection. Act Dermatol 44: 89-91

Authors

Last updated on: 03.12.2022